Stanford bioengineers have invented a way to observe and report on the behavior of family of signaling proteins as they go about their crucial work inside living cells.
Think of the human body as an intricate machine whose working parts are proteins: molecules that change shape to enable our organs and tissues to perform tasks such as breathing or eating or thinking.
Of the millions of protein types, 500 in the kinase family are particularly important to drug discovery. Kinases are messengers: They deliver signals that regulate and orchestrate the actions of other proteins. Proper kinase activity maintains health. Irregular activity is linked to cancer and other diseases. For this reason, many drugs seek either to boost or suppress kinase activity.
Now Stanford bioengineers have invented a way to observe and report on the behavior of these signaling proteins as they go about their crucial work inside living cells.
“We’ve been able to observe multiple kinases functioning in living cells, which is something no one else has ever seen,” said Markus Covert, PhD, an assistant professor of bioengineering and senior author of a paper, published online June 19th in Cell, that describes the findings.
“Cancers can occur when a kinase inappropriately tells a cell to ‘grow, grow, grow,’” Covert said. “The reverse can also be true, if a cell reaches what should be the end of its normal life span but the kinase never says ‘die, die, die.’”
Using the new technique, researchers could observe and compare kinase activity in healthy versus diseased cells, then introduce an experimental drug to see how it affects the living cell.
Read more . . .
The Latest on: Kinases
[google_news title=”” keyword=”Kinases” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Kinases
- BMS and Zai Lab’s Augtyro gains NMPA approval to treat NSCLCon May 13, 2024 at 11:29 am
The approval was supported by the TRIDENT-1 trial studying Augtyro in TKI-naïve and TKI-pretreated patients with ROS1-positive NSCLC.
- Trustees Elect New Member, Reelect Two, and Recognize Dedicated Service to the Collegeon May 13, 2024 at 11:25 am
Prior to his arrival, Kohorn and colleagues at Duke University discovered a family of proteins called “wall-associated kinases”—or WAKs—giving rise to a subdiscipline in plant cell biology. It’s ...
- New insights into Chaga mushroom's mechanisms for fighting oral canceron May 13, 2024 at 7:35 am
They examined whether 200.0 µg/mL of the Chaga extract affected p38 mitogen-activated protein kinases (MAPKs)- and nuclear factor kappa B (NF-Κb)-stimulated apoptosis in the treated cells. The extract ...
- Pipeline Moves: Phase III completion for Corcept’s relaorilanton May 13, 2024 at 4:09 am
This week on Pipeline Moves, we kick off by looking at the completion of a Phase III trial by Corcept Therapeutics of its candidate relacorilant in Cushing’s syndrome. Meanwhile, Regeneron has ...
- Week In Review: Sciwind, Sino Biological And Biocytogen Announce Dealson May 12, 2024 at 12:45 am
ChinaBio's latest Week in Review takes a look at the deals announced by Sciwind, Sino Biological and Biocytogen. Click here for the latest biotech develoments.
- Getting to know the enzymes behind cell communication—and tumor growthon May 8, 2024 at 9:10 am
In the human body, molecules known as kinases propagate signals within and between cells, relaying signals that allow cells to respond to changes in the environment. However, there are hundreds of ...
- Getting to know the enzymes behind cell communication — and tumor growthon May 7, 2024 at 5:00 pm
In the human body, molecules known as kinases propagate signals within and between cells, relaying signals that allow cells to respond to changes in the environment. But there are hundreds of ...
- Deciphera Catapults 72% After Ono Pharmaceutical Agrees To Buy It For $2.4 Billionon April 29, 2024 at 7:22 am
Deciphera stock rocketed to a three-year high Monday after Ono Pharmaceutical agreed to buy it for $2.4 billion.
- Deciphera to be acquired by Japan’s Ono in all-cash deal valued at $2.4 billionon April 29, 2024 at 4:40 am
The price is equal to a 74.7% premium over Deciphera’s closing share price of $14.65 on Friday, and a premium of 68.8% to its 30-trading-day volume weighted average price as of Friday. The deal has ...
- AMP-activated/SNF1 protein kinases: conserved guardians of cellular energyon November 30, 2021 at 1:56 am
The AMPK/SNF1 kinases exist as heterotrimeric complexes that are composed of catalytic α-subunits, β-subunits that bind to glycogen particles, and γ-subunits with tandem domains that bind AMP ...
via Bing News